TriangleNY-ESO-1 TCR/IL-15 Cord Blood NK Cells (NCT06066359)
NY-ESO-1 TCR/IL-15 Cord Blood NK Cells trial for Relapsed/Refractory Myeloma (NCT06066359). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for multiple myeloma that has returned or not responded after at least two earlier lines of treatment, in tumors that carry NY-ESO-1.
The idea: give myeloma a new target for natural killer cells. The cells come from donated umbilical cord blood and are engineered with a receptor aimed at NY-ESO-1, together with interleukin-15. Patients receive chemotherapy, then one infusion of the cells. Those without a complete response may receive up to three more.
The first question is safety and the best cell dose. At MD Anderson in Houston, Muzaffar Qazilbash leads this early study.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.